Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.
Africa
Ethiopia
breast cancer
estrogen receptor
immunohistochemistry
subtype
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
06
2023
accepted:
20
10
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Different biological characteristics, therapeutic responses, and disease-specific outcomes are associated with different molecular subtypes of breast cancer (BC). Although there have been different studies on BC in the Ethiopian capital city of Addis Ababa, there have been few studies in other parts of the nation, and none have evaluated biological characteristics in other locations in the context of the extensive ethnic and genetic diversity found in Ethiopia. This study was carried out to evaluate the distribution of immunohistochemistry (IHC) subtypes of BCs throughout four Ethiopian regions. A total of 227 formalin-fixed paraffin-embedded (FFPE) tissue blocks were collected from tertiary hospitals in four Ethiopian regions between 2015 and 2021. The IHC staining was performed for subtyping, ER, PR, HER2, and Ki-67 proliferation markers. The mean age at diagnosis was 43.9 years. The percentage of ER and PR-negative tumors were 48.3% and 53.2%, respectively. The IHC subtypes showed the following distribution: 33.1% triple-negative breast cancer (TNBC), 27.6% luminal B, 25.2% luminal A, and 14.1% HER2 enriched. In multiple logistic regression analysis, grade III and HER2 positivity were associated with larger tumor size, and also originating from Jimma compared to Mekele. Patients with ER-negative, PR-negative, and TNBC were found in 48.3%, 53.2%, and 33.1% of cases, respectively, showing that half the patients could potentially benefit from endocrine treatment. A considerably high prevalence of TNBC was reported in our study, demanding additional research that includes genetic predisposition factors. Additionally, aggressive tumors were found in a high percentage of younger age groups, which must be considered when planning personalized treatment strategies.
Identifiants
pubmed: 38027092
doi: 10.3389/fendo.2023.1250189
pmc: PMC10666628
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Receptors, Estrogen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250189Informations de copyright
Copyright © 2023 Belachew, Desta, Gebremariam, Deneke, Ashenafi, Yeshi, Fenta, Alem, Alemu, Abafogi, Desta, Chanyalew, Beshah, Taylor, Bauer, Tsehay, Girma, Melka, Tessema, Kantelhardt and Howe.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Med Insights Pathol. 2015 Dec 21;8:23-31
pubmed: 26740749
Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382
pubmed: 29846104
Asian Pac J Cancer Prev. 2012;13(10):5047-52
pubmed: 23244108
Breast Care (Basel). 2020 Aug;15(4):337-346
pubmed: 32982643
Horm Cancer. 2020 Oct;11(5-6):240-249
pubmed: 32772262
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Cancer Biol Ther. 2010 Nov 15;10(10):955-60
pubmed: 21057215
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
BMC Womens Health. 2021 Dec 20;21(1):423
pubmed: 34930226
Breast Cancer Res Treat. 2022 Dec;196(3):495-504
pubmed: 36282363
Cancers (Basel). 2021 Mar 09;13(5):
pubmed: 33803148
Am J Pathol. 2018 Feb;188(2):271-279
pubmed: 29137951
Asian Pac J Cancer Prev. 2016;17(4):1973-8
pubmed: 27221883
Cancer Discov. 2022 Nov 2;12(11):2530-2551
pubmed: 36121736
BMJ Open. 2022 May 27;12(5):e055735
pubmed: 35623750
Breast Cancer Res. 2021 Feb 1;23(1):17
pubmed: 33526044
J Oncol. 2020 Apr 22;2020:9752952
pubmed: 32377198
Asian Pac J Cancer Prev. 2014;15(19):8395-400
pubmed: 25339035
PLoS One. 2017 Feb 13;12(2):e0171024
pubmed: 28192444
Cancer Treat Rev. 2020 Aug;88:102064
pubmed: 32622272
Breast Care (Basel). 2021 Oct;16(5):484-490
pubmed: 34720808
Cancer Causes Control. 2020 Apr;31(4):393-402
pubmed: 32124187
World J Oncol. 2020 Aug;11(4):165-172
pubmed: 32849957
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Ann Diagn Pathol. 2014 Feb;18(1):21-6
pubmed: 24321463
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
World J Clin Oncol. 2014 Aug 10;5(3):382-92
pubmed: 25114853
JCO Glob Oncol. 2022 Mar;8:e2100359
pubmed: 35436143
BMC Womens Health. 2020 Feb 27;20(1):38
pubmed: 32103774
Lancet Glob Health. 2016 Dec;4(12):e923-e935
pubmed: 27855871
Lancet. 2017 Feb 25;389(10071):847-860
pubmed: 27814965
J Glob Oncol. 2019 Jul;5:1-11
pubmed: 31291138
World J Clin Oncol. 2020 Nov 24;11(11):935-944
pubmed: 33312887
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2009 Apr;20(4):628-35
pubmed: 19074747
BMC Cancer. 2011 Jul 12;11:292
pubmed: 21749714
JCO Glob Oncol. 2021 Sep;7:1462-1471
pubmed: 34623906
Breast. 2015 Oct;24(5):642-8
pubmed: 26279132
Pan Afr Med J. 2019 May 14;33:22
pubmed: 31312338
BMC Cancer. 2014 Nov 29;14:895
pubmed: 25433805
Mol Oncol. 2010 Jun;4(3):192-208
pubmed: 20452298
Breast. 2006 Feb;15(1):90-5
pubmed: 16473740
BMC Womens Health. 2018 Feb 14;18(1):40
pubmed: 29444670
Cancers (Basel). 2018 Dec 14;10(12):
pubmed: 30558195
Nat Commun. 2021 Jun 11;12(1):3581
pubmed: 34117245
Am J Hum Genet. 2012 Jul 13;91(1):83-96
pubmed: 22726845
BMC Cancer. 2017 Dec 1;17(1):804
pubmed: 29191181
Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1848-55
pubmed: 22989461
Breast Cancer Res Treat. 2005;93 Suppl 1:S3-10
pubmed: 16247594
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Breast. 2022 Dec;66:15-23
pubmed: 36084384
Ann Oncol. 2010 Oct;21 Suppl 7:vii107-11
pubmed: 20943602
Breast Cancer Res Treat. 2018 Jul;170(1):111-118
pubmed: 29479644
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Ann Oncol. 2018 Feb 1;29(2):405-417
pubmed: 29092024
BMC Womens Health. 2011 Sep 30;11:44
pubmed: 21961708
PLoS Med. 2014 Sep 09;11(9):e1001720
pubmed: 25202974
Pathol Oncol Res. 2011 Sep;17(3):753-8
pubmed: 21479875
Breast. 2012 Jun;21(3):289-95
pubmed: 22277312
Histopathology. 2008 Mar;52(4):445-56
pubmed: 18315597
Clin Med Res. 2009 Jun;7(1-2):4-13
pubmed: 19574486
BMC Genomics. 2006 Apr 27;7:96
pubmed: 16643655
J Glob Oncol. 2018 Sep;4:1-12
pubmed: 30241184
Breast Cancer Res. 2007;9(1):R6
pubmed: 17239243